Mizuho Securities analyst Difei Yang maintained a Buy rating on Spark Therapeutics (NASDAQ: ONCE) today. The company’s shares closed yesterday at $56.01.
Yang wrote:
“We further think it is pre-mature to draw the conclusion that SPK-8011 is inferior to the competing product from BioMarin (BMRN, non-rated). We reduce our PT from $91 to $77 after removing the M&A premium of our valuation per revised valuation methodology and we maintain our revenue forecasts.”
According to TipRanks.com, Yang is a top 100 analyst with an average return of 22.8% and a 54.8% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Alder Biopharmaceuticals, and Audentes Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Spark Therapeutics with a $73.08 average price target, which is a 30.5% upside from current levels. In a report released yesterday, William Blair also maintained a Buy rating on the stock.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $96.59 and a one-year low of $41.06. Currently, Spark Therapeutics has an average volume of 666.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases.
Read More on ONCE:
